Butamben


w63



General information:


Withdrawn ID: w63
Canonical SMILES:
Standard InChI:
Standard InChIKey:
ATC class(es): N
Molecular Formula: C11H15NO2
Molweight: 193.242



Withdrawal information:


Withdrawn due to drug safety reasons:Yes
First withdrawn: 1964
Last withdrawn: 1964
Reference: https://www.ncbi.nlm.nih.gov/pubmed/21574210



Side-effects:

Total reported cases (submitted by medical professionals) with Butamben as primary suspect: 18


Reported final outcomes:
Hospitalization (initial or prolonged): 8
Life-Threatening condition: 7
Disability: 1
Intervention required to prevent permanent impairment/damage: 1


Reported side-effects:

Side-effect Case number
METHAEMOGLOBINAEMIA9
HYPOXIA5
DYSPNOEA5
OXYGEN SATURATION DECREASED3
OROPHARYNGEAL PAIN2
ACQUIRED METHAEMOGLOBINAEMIA2
Fatigue2
PHARYNGEAL OEDEMA2
Cyanosis2
THROAT IRRITATION2
POST PROCEDURAL COMPLICATION1
Product expiration date issue1
SELF-MEDICATION1
Pallor1
SKIN DISCOLOURATION1
THROAT TIGHTNESS1
TREMOR1
INCORRECT DOSE ADMINISTERED1
NO REACTION ON PREVIOUS EXPOSURE TO DRUG1
INJURY1
HEART RATE INCREASED1
EYE ROLLING1
Dizziness1
DEPRESSED LEVEL OF CONSCIOUSNESS1
CONVULSION1
COMA1
BLOOD PRESSURE INCREASED1
Blood pressure decreased1
Blood methaemoglobin present1





Filtered ChEMBL targets:

Target UniProtKB ID Activity in nm Target Name Target gene
P02545 7079.5 Prelamin-A/C LMNA_HUMAN



Toxicity information:

Toxicity class: 5
Toxicity type: dermatological
LD50: 5000 mg/kg



External links:

ChEBML: CHEMBL127516
DrugBank: